Sign in
Taking peoplePhase 4

Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation Stroke

Key facts

Who runs it
Shandong Provincial Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
432 people, planned
Started
1 Oct 2021
Expected to end
1 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Edaravone
  • Edaravone Dexborneol
Record updated
12 November 2026

Who can take part

Age
35 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (13)Hide the full registry criteria

Who can take part

  • Acute anterior circulation ischemic stroke within 48 hours of onset
  • Age 35-80 years
  • NIHSS score 4-24
  • Pre-stroke mRS score ≤1
  • Signed informed consent

Who cannot take part

  • Intracranial hemorrhage
  • Moyamoya disease, vasculitis, or other immune-related infarcts
  • Combined tumor, intracranial infection, epilepsy, or severe systemic disease
  • History of non-lacunar ischemic stroke within 6 months
  • Lacunar infarction or multiple punctate infarcts
  • Severe liver or kidney dysfunction
  • MRI contraindications
  • Participating in other clinical trials

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Acute ischemic stroke

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This multicenter randomized controlled trial evaluates the effect of edaravone dexborneol on blood-brain barrier repair in patients with acute anterior circulation large artery atherosclerotic ischemic stroke within 48 hours of onset.

Read full original descriptionShow less

Patients are randomized 1:1 to receive either edaravone dexborneol (30mg/7.5mg BID IV) or edaravone (30mg BID IV) for 9±2 days, in addition to standard stroke treatment. The primary outcome is the change in blood-brain barrier permeability (Ktrans) measured by DCE-MRI. Secondary outcomes include neurological function scores, serum biomarkers, and safety events.

The 2 groups in the trial

  • Control GroupExisting treatment, for comparison

    Participants receive edaravone 30mg BID intravenous drip for 9±2 days, plus standard stroke treatment.

    Treatment: Edaravone

  • Intervention GroupTreatment being tested

    Participants receive edaravone dexborneol 30mg/7.5mg BID intravenous drip for 9±2 days, plus standard stroke treatment.

    Treatment: Edaravone Dexborneol

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter Randomized Controlled Trial Study of the Effect of Edaravone and Dexcamphan on the Repair of Blood-brain Barrier Injury in Acute Infarction of Anterior Circulation
Criteria questions
Built from NCT07933692, who can take part
Record updated
12 November 2026